localized Castleman disease

Summary

localized Castleman disease (MONDO:0019753) is a disease and 1 clinical trial. A subtype of Castleman disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000		United States	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	localized Castleman disease
Mondo ID	MONDO:0019753
Orphanet	93685
NCIT	C115200
UMLS	C3898582
MedGen	858176
GARD	0006005
Is cancer (heuristic)	no

Also known as: localised Angiofollicular lymphoid hyperplasia · localized Angiofollicular lymphoid hyperplasia · localized Castleman disease · Unicentric angiofollicular ganglionic hyperplasia · Unicentric angiofollicular lymph hyperplasia · Unicentric Castleman disease

Disease family

This is a subtype of Castleman disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › inborn error of immunity › lymphoproliferative syndrome › Castleman disease › localized Castleman disease

Related subtypes (3): pediatric Castleman disease, multicentric Castleman disease, idiopathic multicentric Castleman disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05440305	Not specified	COMPLETED	Unicentric Form of Castleman Disease - Surgery Therapy Benefit